|
Dec 9
|
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
|
|
Dec 5
|
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
|
|
Nov 7
|
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
|
|
Nov 2
|
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
|
|
Oct 26
|
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
|
Sep 13
|
Adaptive Announces Launch of Epic Integration for clonoSEQ®
|
|
Jul 19
|
Viking Global’s Performance, AUM, and Long-Term Stock Picks
|